Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial
- 16 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 316-323
- https://doi.org/10.1016/j.jcf.2020.12.004
Abstract
No abstract availableKeywords
Funding Information
- Channel 7 Telethon Trust
- Princess Margaret Hospital Foundation
This publication has 23 references indexed in Scilit:
- Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung InfectionPLOS ONE, 2013
- Edetate calcium disodium nanoparticle dry powder inhalation: A novel approach against heavy metal decorporationInternational Journal of Pharmaceutics, 2011
- Efficacy of Calcium-EDTA as an Inhibitor for Metallo-β-Lactamase in a Mouse Model of Pseudomonas aeruginosa PneumoniaAntimicrobial Agents and Chemotherapy, 2010
- Tobramycin and FDA-Approved Iron Chelators Eliminate Pseudomonas aeruginosa Biofilms on Cystic Fibrosis CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patientsJournal of Cystic Fibrosis, 2003
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002
- Role of chelating agents for prevention, intervention, and treatment of exposures to toxic metals.Environmental Health Perspectives, 1995
- Antimicrobial effect of combinations of EDTA-Tris and amikacin or neomycin on the microorganisms associated with otitis externa in dogsVeterinary Research Communications, 1994
- Use of induced sputum cell counts to investigate airway inflammation in asthma.Thorax, 1992
- AEROSOL EDTA TO ELIMINATE RESPIRATORY-TRACT PSEUDOMONASThe Lancet, 1984